» Articles » PMID: 27406095

Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2016 Jul 14
PMID 27406095
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Young age at breast cancer diagnosis has been associated with increased risk of recurrence and mortality. We reevaluated this assumption in a large, modern cohort of women diagnosed with breast cancer at age ≤40 years.

Methods: We identified women with breast cancer at age ≤40 years at a single institution from 1996-2008. We assessed locoregional recurrence (LRR), distant recurrence, disease-free survival (DFS), and overall survival (OS), and correlated patient and tumor characteristics with outcomes.

Results: We identified 584 women aged ≤40 years with breast cancer. Median age was 37 years, and median follow-up was 124 months; 61.5 % were stages 0-I and 38.5 % were stages II-III. Overall, 57.4 % had lumpectomies and 42.5 % mastectomies. DFS was 93 % at 5 years and 84.5 % at 10 years. OS was 93 % at 5 years and 86.5 % at 10 years. On multivariate analysis, worse DFS was associated with positive nodes (p = 0.002); worse OS was associated with larger tumor size (p = 0.042). When stratified by lumpectomy versus mastectomy, there were no significant differences in survival or recurrence. For lumpectomy patients, DFS was 96 % at 5 years and 88 % at 10 years; OS was 96 % at 5 years and 89 % at 10 years. For mastectomy patients, DFS was 89.5 % at 5 years and 79 % at 10 years; OS was 90 % at 5 years and 83 % at 10 years. Lumpectomy LRR rates were 1 % at 5 years and 4 % at 10 years. Mastectomy LRR rates were 3.5 % at 5 years and 8.7 % at 10 years.

Conclusions: Outcomes for women with breast cancer at age ≤40 years have improved. Lumpectomy recurrence rates are low, suggesting that lumpectomy is oncologically safe for young breast cancer patients.

Citing Articles

Risk Factors for Positive Resection Margins in Breast-Conserving Surgery for Breast Cancer-Retrospective Analysis.

Georgescu R, Tutuianu F, Bauer O, Toganel A, Benedek Z, Darii E Cancers (Basel). 2024; 16(17).

PMID: 39272788 PMC: 11394422. DOI: 10.3390/cancers16172930.


The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.

Boutrus R, Abdelazim Y, Mohammed T, Bayomy M, Ibraheem M, Hussein A BMC Cancer. 2024; 24(1):599.

PMID: 38760780 PMC: 11100067. DOI: 10.1186/s12885-024-12325-3.


The unifying concepts of the sick lobe hypothesis, field cancerisation and breast conservation treatment for multiple ipsilateral breast cancers: a narrative review.

Tan M, Sitoh Y Gland Surg. 2023; 12(4):535-547.

PMID: 37200923 PMC: 10186170. DOI: 10.21037/gs-22-609.


The role of tumor phenotype in the surgical treatment of early-stage breast cancer.

Rooney M, Thomas S, Taskindoust M, Greenup R, Rosenberger L, Hwang E Am J Surg. 2022; 225(1):84-92.

PMID: 36180300 PMC: 9912362. DOI: 10.1016/j.amjsurg.2022.09.029.


Short term recurrence and survival rate of breast cancer patients post surgical treatment; north borneo experience.

Kumilau R, Hayati F, Liew J, Sharif S, Nik Lah N Ann Med Surg (Lond). 2022; 81:104560.

PMID: 36147066 PMC: 9486850. DOI: 10.1016/j.amsu.2022.104560.